Mangoceuticals (NASDAQ:MGRX – Get Free Report) released its earnings results on Monday. The company reported ($0.19) earnings per share (EPS) for the quarter, FiscalAI reports. Mangoceuticals had a negative return on equity of 96.39% and a negative net margin of 4,794.60%. The firm had revenue of $0.07 million during the quarter.
Mangoceuticals Stock Down 1.4%
MGRX traded down $0.00 during trading hours on Tuesday, reaching $0.16. 209,259 shares of the company’s stock traded hands, compared to its average volume of 7,673,512. The firm has a 50-day moving average price of $0.34 and a 200 day moving average price of $0.39. Mangoceuticals has a 52-week low of $0.15 and a 52-week high of $1.38. The firm has a market capitalization of $3.41 million, a PE ratio of -0.16 and a beta of 2.15.
Analysts Set New Price Targets
A number of analysts recently weighed in on MGRX shares. Wall Street Zen raised shares of Mangoceuticals to a “sell” rating in a research report on Saturday, July 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Mangoceuticals in a research note on Monday, September 21st. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has an average rating of “Sell”.
Check Out Our Latest Analysis on Mangoceuticals
About Mangoceuticals
Mangoceuticals, Inc. is a men’s health and wellness company that offers telehealth services through its online platform. The platform connects customers with healthcare providers for consultations and, when appropriate, prescription treatments. The company’s offerings have included treatments for erectile dysfunction, hair loss and testosterone-related concerns, as well as weight-management services. Prescriptions are fulfilled through pharmacy partners. Mangoceuticals primarily serves customers in the United States through its digital platform.
Read More
- Five stocks we like better than Mangoceuticals
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
